← Back to Search

Fibrinolytic Agent

Operative VATS decortication for Pleural Empyema

N/A
Waitlist Available
Led By Fredric Pieracci, MD, MPH
Research Sponsored by Denver Health and Hospital Authority
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up everyday for 5 days post study intervention, from admission to discharge, or for 28 days, whichever comes first.
Awards & highlights

Summary

This study aims to standardize the treatment of pleural space (parapneumonic) infections by comparing the difference in outcomes between 2 methods of treatment: early VATS (Video Assisted Thorascopic Surgery) decortication versus fibrinolytic therapy. During treatment, the patient's coagulopathy status will also be evaluated.

Eligible Conditions
  • Pleural Empyema
  • Parapneumonic Effusion
  • Blood Clotting Disorder

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~everyday for 5 days post study intervention, from admission to discharge, or for 28 days, whichever comes first.
This trial's timeline: 3 weeks for screening, Varies for treatment, and everyday for 5 days post study intervention, from admission to discharge, or for 28 days, whichever comes first. for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Hospital Length of Stay
Secondary study objectives
Changed in Coagulopathic Status
Chest Tube Days
Chest Tube Drainage
+8 more

Trial Design

2Treatment groups
Active Control
Group I: Operative VATS decorticationActive Control1 Intervention
Operative group that will undergo early VATS decortication of complicated parapneumonic effusion/empyema
Group II: Non-operative Fibrinolytic TherapyActive Control1 Intervention
Non-operative group that will undergo instillation of the drugs DNAse and tPA (tissue plasminogen activator) together i.e. 5mg DNAse and 10mg tPA twice a day for up to six doses, through chest tube as treatment of the patient's complicated parapneumonic effusion/empyema. Fibrinolytic therapy = DNAse + tPA; these medications are not mutually exclusive.

Find a Location

Who is running the clinical trial?

Denver Health and Hospital AuthorityLead Sponsor
104 Previous Clinical Trials
402,111 Total Patients Enrolled
Fredric Pieracci, MD, MPHPrincipal InvestigatorDenver Health and Hospital
~1 spots leftby Sep 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top